TolDCB29

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameTolDCB29

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapyCell and gene therapy > Cell therapy > Source of cells > Tolerogenic monocyte-derived

Mechanisms of ActionB-cell antigen receptor complex-associated protein beta chain modulators

TargetsB-cell antigen receptor complex-associated protein beta chain

Therapy Area/IndicationsArthritis, Rheumatoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesUmc Utrecht

China Registration ClassN/A

Develop Information

Active CompaniesUmc Utrecht

Inactive CompaniesN/A

Active IndicationsArthritis, Rheumatoid

Inactive IndicationsN/A

Other Information

ATC CodeN/A